Literature DB >> 24605840

Incidence and predictors of 30-day readmission for patients discharged home after craniotomy for malignant supratentorial tumors in California (1995-2010).

Logan P Marcus1, Brandon A McCutcheon, Abraham Noorbakhsh, Ralitza P Parina, David D Gonda, Clark Chen, David C Chang, Bob S Carter.   

Abstract

OBJECT: Hospital readmission within 30 days of discharge is a major contributor to the high cost of health care in the US and is also a major indicator of patient care quality. The purpose of this study was to investigate the incidence, causes, and predictors of 30-day readmission following craniotomy for malignant supratentorial tumor resection.
METHODS: The longitudinal California Office of Statewide Health Planning & Development inpatient-discharge administrative database is a data set that consists of 100% of all inpatient hospitalizations within the state of California and allows each patient to be followed throughout multiple inpatient hospital stays, across multiple institutions, and over multiple years (from 1995 to 2010). This database was used to identify patients who underwent a craniotomy for resection of primary malignant brain tumors. Causes for unplanned 30-day readmission were identified by principle ICD-9 diagnosis code and multivariate analysis was used to determine the independent effect of various patient factors on 30-day readmissions.
RESULTS: A total of 18,506 patients received a craniotomy for the treatment of primary malignant brain tumors within the state of California between 1995 and 2010. Four hundred ten patients (2.2%) died during the index surgical admission, 13,586 patients (73.4%) were discharged home, and 4510 patients (24.4%) were transferred to another facility. Among patients discharged home, 1790 patients (13.2%) were readmitted at least once within 30 days of discharge, with 27% of readmissions occurring at a different hospital than the initial surgical institution. The most common reasons for readmission were new onset seizure and convulsive disorder (20.9%), surgical infection of the CNS (14.5%), and new onset of a motor deficit (12.8%). Medi-Cal beneficiaries were at increased odds for readmission relative to privately insured patients (OR 1.52, 95% CI 1.20-1.93). Patients with a history of prior myocardial infarction were at an increased risk of readmission (OR 1.64, 95% CI 1.06-2.54) as were patients who developed hydrocephalus (OR 1.58, 95% CI 1.20-2.07) or venous complications during index surgical admission (OR 3.88, 95% CI 1.84-8.18).
CONCLUSIONS: Using administrative data, this study demonstrates a baseline glioma surgery 30-day readmission rate of 13.2% in California for patients who are initially discharged home. This paper highlights the medical histories, perioperative complications, and patient demographic groups that are at an increased risk for readmission within 30 days of home discharge. An analysis of conditions present on readmission that were not present at the index surgical admission, such as infection and seizures, suggests that some readmissions may be preventable. Discharge planning strategies aimed at reducing readmission rates in neurosurgical practice should focus on patient groups at high risk for readmission and comprehensive discharge planning protocols should be implemented to specifically target the mitigation of potentially preventable conditions that are highly associated with readmission.

Entities:  

Mesh:

Year:  2014        PMID: 24605840     DOI: 10.3171/2014.1.JNS131264

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  19 in total

Review 1.  Tumor-related epilepsy: epidemiology, pathogenesis and management.

Authors:  Dillon Y Chen; Clark C Chen; John R Crawford; Sonya G Wang
Journal:  J Neurooncol       Date:  2018-05-24       Impact factor: 4.130

2.  Readmission risk of malignant brain tumor patients undergoing laser interstitial thermal therapy (LITT) and stereotactic needle biopsy (SNB): a covariate balancing weights analysis of the National Readmissions Database (NRD).

Authors:  Truong H Do; Madeleine A Howard; Elise F Palzer; Jared D Huling; Mohammed A Alvi; Samuel W Cramer; Ping Zhu; Reid A Johnson; James Jean; Jinci Lu; Alec B Jonason; Jacob Hanson; Luke Sabal; Kevin W Sun; Robert A McGovern; Clark C Chen
Journal:  J Neurooncol       Date:  2022-07-23       Impact factor: 4.506

3.  Predictors of 30-day readmission after aneurysmal subarachnoid hemorrhage: a case-control study.

Authors:  Jacob K Greenberg; Ridhima Guniganti; Eric J Arias; Kshitij Desai; Chad W Washington; Yan Yan; Hua Weng; Chengjie Xiong; Emily Fondahn; DeWitte T Cross; Christopher J Moran; Keith M Rich; Michael R Chicoine; Rajat Dhar; Ralph G Dacey; Colin P Derdeyn; Gregory J Zipfel
Journal:  J Neurosurg       Date:  2016-08-05       Impact factor: 5.115

Review 4.  Antiepileptic Drugs in the Management of Cerebral Metastases.

Authors:  Meredith A Monsour; Patrick D Kelly; Lola B Chambless
Journal:  Neurosurg Clin N Am       Date:  2020-10       Impact factor: 2.509

5.  Smoking and Obesity are Risk Factors for Thirty-Day Readmissions Following Skull Base Surgery.

Authors:  Milan Makwana; Peter N Taylor; Benjamin T Stew; Geoffrey Shone; Caroline Hayhurst
Journal:  J Neurol Surg B Skull Base       Date:  2019-04-02

6.  Readmission after neurosurgical intervention in epilepsy: A nationwide cohort analysis.

Authors:  Churl-Su Kwon; Parul Agarwal; Varsha Subramaniam; Mandip Dhamoon; Madhu Mazumdar; Anusha Yeshokumar; Fedor Panov; Saadi Ghatan; Nathalie Jetté
Journal:  Epilepsia       Date:  2019-12-02       Impact factor: 5.864

7.  Predictors of 30- and 90-day readmission following craniotomy for malignant brain tumors: analysis of nationwide data.

Authors:  Daniel A Donoho; Timothy Wen; Robin M Babadjouni; William Schwartzman; Ian A Buchanan; Steven Y Cen; Gabriel Zada; William J Mack; Frank J Attenello
Journal:  J Neurooncol       Date:  2017-10-07       Impact factor: 4.130

8.  Readmission following inpatient stereotactic radiosurgery for brain tumors.

Authors:  Austin M Tang; Joshua Bakhsheshian; Michelle Lin; Casey A Jarvis; Edith Yuan; Ian A Buchanan; Li Ding; Ben A Strickland; Eric Chang; Gabriel Zada; William J Mack; Frank J Attenello
Journal:  J Radiosurg SBRT       Date:  2019

Review 9.  A clinical care pathway to improve the acute care of patients with glioma.

Authors:  Natalie B V Riblet; Evelyn M Schlosser; Jennifer A Snide; Lara Ronan; Katherine Thorley; Melissa Davis; Jennifer Hong; Linda P Mason; Tobi J Cooney; Lanelle Jalowiec; Nancy L Kennedy; Sabrina Richie; David Nalepinski; Camilo E Fadul
Journal:  Neurooncol Pract       Date:  2015-10-23

10.  Costs and Complications Associated With Resection of Supratentorial Tumors With and Without the Operative Microscope in the United States.

Authors:  Yi Zhang; Michael Zhang; Matthew Lin; Melanie Hayden Gephart; Anand Veeravagu; John K Ratliff; Gordon Li
Journal:  World Neurosurg       Date:  2020-03-30       Impact factor: 2.210

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.